Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Identifying distinct classes of bladder carcinoma using microarrays

Abstract

Bladder cancer is a common malignant disease characterized by frequent recurrences1,2. The stage of disease at diagnosis and the presence of surrounding carcinoma in situ are important in determining the disease course of an affected individual3. Despite considerable effort, no accepted immunohistological or molecular markers have been identified to define clinically relevant subsets of bladder cancer. Here we report the identification of clinically relevant subclasses of bladder carcinoma using expression microarray analysis of 40 well characterized bladder tumors. Hierarchical cluster analysis identified three major stages, Ta, T1 and T2-4, with the Ta tumors further classified into subgroups. We built a 32-gene molecular classifier using a cross-validation approach that was able to classify benign and muscle-invasive tumors with close correlation to pathological staging in an independent test set of 68 tumors. The classifier provided new predictive information on disease progression in Ta tumors compared with conventional staging (P < 0.005). To delineate non-recurring Ta tumors from frequently recurring Ta tumors, we analyzed expression patterns in 31 tumors by applying a supervised learning classification methodology, which classified 75% of the samples correctly (P < 0.006). Furthermore, gene expression profiles characterizing each stage and subtype identified their biological properties, producing new potential targets for therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Two-way hierarchical clustering and multidimensional scaling analysis of gene expression data from 40 bladder tumor biopsy samples.
Figure 2: Enlarged view of gene clusters a, c, f and g.
Figure 3: Molecular classification of bladder tumor stages and identification of genes that predict recurrence.

Similar content being viewed by others

Accession codes

Accessions

Gene Expression Omnibus

References

  1. Pisani, P., Parkin, D.M., Bray, F. & Ferlay, J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer 83, 18–29 (1999).

    Article  CAS  Google Scholar 

  2. Wolf, H. et al. Bladder tumors. Treated natural history. Prog. Clin. Biol. Res. 221, 223–255 (1986).

    CAS  PubMed  Google Scholar 

  3. Cheng, L. et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 85, 2469–2474 (1999).

    Article  CAS  Google Scholar 

  4. Golub, T.R. et al. Molecular classification of cancer: class discovery and class prediction by gene-expression monitoring. Science 286, 531–537 (1999).

    Article  CAS  Google Scholar 

  5. Khan, J. et al. Classification and diagnostic prediction of cancers using gene-expression profiling and artificial neural networks. Nat. Med. 7, 673–679 (2001).

    Article  CAS  Google Scholar 

  6. Perou, C.M. et al. Molecular portraits of human breast tumors. Nature 406, 747–752 (2000).

    Article  CAS  Google Scholar 

  7. Alizadeh, A.A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene-expression profiling. Nature 403, 503–511 (2000).

    Article  CAS  Google Scholar 

  8. Ross, D.T. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24, 227–235 (2000).

    Article  CAS  Google Scholar 

  9. Takahashi, M. et al. Gene-expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl. Acad. Sci. USA 98, 9754–9759 (2001).

    Article  CAS  Google Scholar 

  10. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869–10874 (2001).

    Article  CAS  Google Scholar 

  11. Shipp, M.A. et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8, 68–74 (2002).

    Article  CAS  Google Scholar 

  12. van't Veer, L.J. et al. Gene-expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).

    Article  CAS  Google Scholar 

  13. Alon, U. et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 96, 6745–6750 (1999).

    Article  CAS  Google Scholar 

  14. Luo, J. et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene-expression profiling. Cancer Res. 61, 4683–4688 (2001).

    CAS  PubMed  Google Scholar 

  15. Notterman, D.A., Alon, U., Sierk, A.J. & Levine, A.J. Transcriptional gene-expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 61, 3124–3130 (2001).

    CAS  PubMed  Google Scholar 

  16. Perou, C.M. et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA 96, 9212–9217 (1999).

    Article  CAS  Google Scholar 

  17. Dhanasekaran, S.M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822–826 (2001).

    Article  CAS  Google Scholar 

  18. Thykjaer, T. et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res. 61, 2492–2499 (2001).

    CAS  PubMed  Google Scholar 

  19. Seymour, L. Novel anti-cancer agents in development: exciting prospects and new challenges. Cancer Treat. Rev. 25, 301–312 (1999).

    Article  CAS  Google Scholar 

  20. Fox, S.B., Gasparini, G. & Harris, A.L. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2, 278–289 (2001).

    Article  CAS  Google Scholar 

  21. Ørntoft, T.F. et al. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. Mol. Cell. Proteomics 1, 37–45 (2002).

    Article  Google Scholar 

  22. Kerr, J.S., Slee, A.M. & Mousa, S.A. Small molecule alpha(v) integrin antagonists: novel anticancer agents. Expert Opin. Investig. Drugs 9, 1271–1279 (2000).

    Article  CAS  Google Scholar 

  23. Bergkvist, A., Ljungqvist, A. & Moberger, G. Classification of bladder tumors based on the cellular pattern. Preliminary report of a clinical–pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir. Scand. 130, 371–378 (1965).

    CAS  PubMed  Google Scholar 

  24. Li, C. & Hung, W.W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2, RESEARCH0032 (2001).

  25. Eisen, M.B., Spellman, P.T., Brown, P.O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863–14868 (1998).

    Article  CAS  Google Scholar 

  26. Kononen, J. et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4, 844–847 (1998).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank K.Y. Jonsdottir for computational assistance, H. Steen, B. Pytlick, J.C. Djurhuus, B. Stougaard and B. Devantié for excellent assistance, and the staff at the Departments of Urology, Clinical Biochemistry and Pathology at Aarhus University Hospital. We acknowledge support from the Karen Elise Jensen Foundation, The Danish Cancer Society, EOS Biotechnology, the John and Birthe Meyers Foundation, The Institute of Experimental Clinical Research, The University and County of Aarhus and the Danish Research Council.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Torben F. Ørntoft.

Ethics declarations

Competing interests

T.F.O., T.T. and M.K. co-founded AROS Applied Biotechnology ApS in the year 2000.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dyrskjøt, L., Thykjaer, T., Kruhøffer, M. et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33, 90–96 (2003). https://doi.org/10.1038/ng1061

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng1061

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing